Among approved drugs, participation of patients over 65 has ranged from 10 percent in 2014 to 39.9 percent in 2020, indicating a consistent increase in the share of elderly participants in trials resulting in FDA approval during this period (2021 data are yet incomplete)
Aging Cell 23 , e14138 (2024)
History, contraindication screen, and indication specific labs are the baseline
[DOI] [PMC free article] [PubMed] [Google Scholar] 161.Aguirre TA, Teijeiro-Osorio D, Rosa M, Coulter I, Alonso M, Brayden D
however, we dont have enough data yet for it to be recommended without reservation
Advantages of Non-invasive Stimulation for Therapeutic Use (L.V